ARWR
Price
$16.79
Change
-$0.11 (-0.65%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
2.32B
39 days until earnings call
CYTK
Price
$34.66
Change
+$0.30 (+0.87%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
4.14B
28 days until earnings call
Interact to see
Advertisement

ARWR vs CYTK

Header iconARWR vs CYTK Comparison
Open Charts ARWR vs CYTKBanner chart's image
Arrowhead Pharmaceuticals
Price$16.79
Change-$0.11 (-0.65%)
Volume$151.66K
Capitalization2.32B
Cytokinetics
Price$34.66
Change+$0.30 (+0.87%)
Volume$95.03K
Capitalization4.14B
ARWR vs CYTK Comparison Chart in %
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. CYTK commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Buy and CYTK is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (ARWR: $16.79 vs. CYTK: $34.66)
Brand notoriety: ARWR: Notable vs. CYTK: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 50% vs. CYTK: 71%
Market capitalization -- ARWR: $2.32B vs. CYTK: $4.14B
ARWR [@Biotechnology] is valued at $2.32B. CYTK’s [@Biotechnology] market capitalization is $4.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileCYTK’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • CYTK’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARWR and CYTK are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 4 TA indicator(s) are bullish while CYTK’s TA Score has 5 bullish TA indicator(s).

  • ARWR’s TA Score: 4 bullish, 4 bearish.
  • CYTK’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а +4.48% price change this week, while CYTK (@Biotechnology) price change was +2.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

ARWR is expected to report earnings on Aug 11, 2025.

CYTK is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.14B) has a higher market cap than ARWR($2.32B). ARWR YTD gains are higher at: -10.691 vs. CYTK (-26.318). ARWR has higher annual earnings (EBITDA): -68.12M vs. CYTK (-513.62M). ARWR has more cash in the bank: 1.1B vs. CYTK (938M). ARWR has less debt than CYTK: ARWR (388M) vs CYTK (791M). ARWR has higher revenues than CYTK: ARWR (545M) vs CYTK (19.2M).
ARWRCYTKARWR / CYTK
Capitalization2.32B4.14B56%
EBITDA-68.12M-513.62M13%
Gain YTD-10.691-26.31841%
P/E RatioN/AN/A-
Revenue545M19.2M2,839%
Total Cash1.1B938M117%
Total Debt388M791M49%
FUNDAMENTALS RATINGS
ARWR vs CYTK: Fundamental Ratings
ARWR
CYTK
OUTLOOK RATING
1..100
6515
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
10082
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
5964
P/E GROWTH RATING
1..100
21
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARWR's Valuation (94) in the Biotechnology industry is in the same range as CYTK (100). This means that ARWR’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as ARWR (100). This means that CYTK’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's SMR Rating (96) in the Biotechnology industry is in the same range as CYTK (100). This means that ARWR’s stock grew similarly to CYTK’s over the last 12 months.

ARWR's Price Growth Rating (59) in the Biotechnology industry is in the same range as CYTK (64). This means that ARWR’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is in the same range as ARWR (2). This means that CYTK’s stock grew similarly to ARWR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRCYTK
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 17 days ago
83%
Bearish Trend 4 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WFDAX26.13N/A
N/A
Allspring SMID Cap Growth Fund - Cl A
LINTX22.50N/A
N/A
Lord Abbett International Opp R5
GCEAX19.06N/A
N/A
AB Global Core Equity A
EIPFX18.59N/A
N/A
EIP Growth and Income Investor
TRQZX103.02N/A
N/A
T. Rowe Price Mid-Cap Growth Z

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-0.65%
DNLI - ARWR
54%
Loosely correlated
-1.41%
RGNX - ARWR
53%
Loosely correlated
+1.39%
IMNM - ARWR
53%
Loosely correlated
+2.43%
YMAB - ARWR
53%
Loosely correlated
+0.94%
BEAM - ARWR
52%
Loosely correlated
+0.65%
More

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IMVT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+0.87%
IMVT - CYTK
48%
Loosely correlated
+0.83%
IDYA - CYTK
48%
Loosely correlated
+0.82%
KRYS - CYTK
46%
Loosely correlated
+1.22%
ROIV - CYTK
44%
Loosely correlated
+0.18%
BEAM - CYTK
44%
Loosely correlated
+0.65%
More